Please login to the form below

Not currently logged in
Email:
Password:

Amgen and Novartis migraine drug hits the mark again

Aimovig will become the first CGRP receptor-targeting drug if it reaches market

Amgen

Amgen and Novartis’ much-anticipated new migraine drug Aimovig has generated positive data in another late-stage trial, halving migraine days in 30% of patients with continued symptoms despite multiple earlier treatments.

The drug - which is vying to become the first calcitonin gene-related peptide (CGRP) receptor-targeting drug to reach the market for migraine - was more than twice as likely to hit this target compared to placebo. In the control group just under 14% of patients achieved a 50% reduction in migraine days.

The 246-patient study involved people with episodic migraine who had previously failed between two and four prior treatments, either because they were ineffective or couldn’t be tolerated, who were randomised to therapy with Aimovig (erenumab) or placebo for 12 weeks.

Improvements with Aimovig were also observed for secondary measures including the number of monthly migraine days and the need for acute treatment for breakthrough migraine attacks.

Amgen R&D chief Sean Harper said: “We are encouraged by these new findings, which add to the growing body of clinical evidence supporting potential use of Aimovig across a broad spectrum of patients with migraine.”

The new data comes just a month before the FDA is due to deliver its verdict on Novartis and Amgen’s marketing application for Aimovig, which is a little ahead of other CGRP drugs in development, a group which includes Eli Lilly's galcanezumab, Teva's fremanezumab and Alder's eptinezumab. The two partners maintain that Aimovig is different to its rivals because they target CGRP itself, as opposed to the receptor pathway.

Lilly’s drug seems to be the closest behind Aimovig, having been filed towards the end of last year, and there is a lot to play for with analysts predicting that the CGRP class could eventually make $4bn in sales by 2026.

The drugs are expected to be used most for severe chronic migraine patients who can't get relief from the current array of therapies, which consists of pain-killing drugs, triptans and repurposed medicines such as the anticonvulsant topiramate or Allergan's Botox.

Article by
Phil Taylor

18th April 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics